Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma:

about

Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma:

Item

http://www.wikidata.org/entity/Q58699240

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@en

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@nl

type

Item

label

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@en

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@nl

prefLabel

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@en

Development of a Robust UPLC M ...... d Daclatasvir in Human Plasma:

@nl

P1476

Development of a Robust UPLC M ...... to Therapeutic Drug Monitoring

@en

P2093

Ahmed Hemdan

http://www.w3.org/2001/XMLSchema#string

Naser F Al-Tannak

http://www.w3.org/2001/XMLSchema#string

P2860

Sofosbuvir: a novel oral agent for chronic hepatitis C

Chronic hepatitis C: This and the new era of treatment

Diagnosis, management, and treatment of hepatitis C: an update

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

Novel and sensitive UPLC-MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study.

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.

Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study.

P304

6535816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/6535816

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Maya S Eissa

P577

2018-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30420886

http://www.w3.org/2001/XMLSchema#string

P921

analytical chemistry

P932

6215565

http://www.w3.org/2001/XMLSchema#string